Dear Valued Reader,
Hello, this is Dr. Perry Brunette, Ph.D., CEO and Founder of PathFree Technologies. Picture this: In the chaos of a Code Blue emergency, our AIMediQ™ rolls in to cut errors by 40%, guiding teams in real-time to save lives that might otherwise be lost. That's the reality we're creating with AIMediQ™ powered by datasyteAI™ right now—and as the visionary behind it, I'm thrilled to share how we're scaling this impact.
What's your perspective on AI transforming emergency care?
From our base in Irvine, California, PathFree Technologies is leading the charge in AI-driven medtech innovation. Our AIMediQ™ platform provides real-time CPR guidance and adaptive rhythm analysis, seamlessly aligning with medical protocols to boost accuracy and save lives in critical moments. With a top-tier investment bank backing our Series A and early hospital pilots, we're poised for explosive growth in the $100B+ medtech market.
I'm excited to invite select accredited investors like you to join us: We're offering up to 5 million shares of common stock at $5 each, starting at $100K, with flexibility for the right partners. If you act now, warrants are included at no cost with your stock purchase for the first $1M raised. Additional warrants are available at $1.25, offering up to 5x leverage, full voting rights, and potential dividends.
This isn't just an investment—it's a chance to partner with me to transform healthcare, with stock options as we hit FDA milestones and expand globally.
Early-stage risks? Absolutely, but our proven AI and strong banking support make this a strategic step forward. (Calculated risk)
Sincerely,
Dr. Perry Brunette, Ph.D.
CEO and Founder,
PathFree Technologies
Please see the information below
What is a Code Blue? Watch this quick explainer video to align yourself on the scenario AIMediQ™ powered by datasyteAI™ supports.
